chylomicronemia

chylomicronemia

 [ki″lo-mi″kro-ne´me-ah]
an excess of chylomicrons in the blood.

chy·lo·mi·cro·ne·mi·a

(kī'lō-mī'krō-nē'mē-ă),
The presence of chylomicrons, especially increased numbers in the circulating blood, as in type I familial hyperlipoproteinemia.
See also: familial chylomicronemia syndrome.

chylomicronemia

/chy·lo·mi·cro·ne·mia/ (-mi″kron-e´me-ah) an excess of chylomicrons in the blood.

chy·lo·mi·cro·ne·mi·a

(kī'lō-mī-krō-nē'mē-ă)
The presence of chylomicrons, especially an increased number, in the circulating blood, as in type I familial hyperlipoproteinemia.
Synonym(s): chylomicronaemia.

chylomicronemia

an excess of chylomicrons in the blood.
References in periodicals archive ?
Drugs currently in Phase 3 development include volanesorsen, a drug Isis is developing and plans to commercialize through its wholly owned subsidiary, Akcea Therapeutics, to treat patients with familial chylomicronemia syndrome and familial partial lipodystrophy; ISIS-TTR[sub.
Thus, homozygosity for rare deleterious mutations in LPL leads to the chylomicronemia syndrome characterized by severely increased triglycerides with excessive accumulation of chylomicrons and very large very-low-density lipoproteins in plasma.
Very severe triglyceride elevations (greater than 2,000 mg/dL) increase the risk of pancreatitis in the chylomicronemia syndrome.
Lomitapide is being evaluated for its ability to reduce LDL-C levels in patients with HoFH and reduce triglyceride levels in patients with familial chylomicronemia, or FC.
i) Familial Chylomicronemia Syndrome with either Lipoprotein Lipase (LPL) Deficiency or Apolipoprotein C II deficiency or
Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome.
Familial chylomicronemia caused by a novel type of mutation in the APOE-CI-CIV-CII gene cluster encompassing both the APOCTI gene and the first APOCIV gene mutation: APOCII-CIV (Nijmegen).
Also, the normal postprandial hypertriglyceridemia and chylomicronemia are dramatically decreased by ingesting fish oil.
In addition, we and Akcea plan to complete enrollment in the Phase 3 study of volanesorsen in patients with familial chylomicronemia syndrome this year.
For instance, some cases of familial chylomicronemia result from mutations in the gene encoding lipoprotein lipase or its cofactor apoC-II.
Patients in this category have primary or secondary disorders of triglyceride metabolism; chylomicronemia is often present.
Akcea's most advanced program, volanesorsen, is in Phase 3 development to treat patients with ultra-orphan lipid disorders that are characterized by extremely high triglycerides and ApoC-III, including familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy (FPL).